Cipla Ltd has signed an agreement with biotech firm Stempeutics Research for its stem cell therapy product Stempeucel, indicated for treating critical limb ischemia. Under this agreement, Cipla will get exclusive marketing rights for five years in India for critical limb ischemia due to atherosclerotic peripheral arterial disease (CLI-PAD) . CLI-PAD is characterised by narrowing of arteries in the legs limiting blood flow to the muscles due to the build-up of fatty deposits called plaque. The product is expected to be available in the Indian market in the beginning of 2020 after undergoing the phase 3 clinical trial in India, which is expected to commence in 2018
Company Profile : Cipla Ltd
Leave a Reply